서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Publisher

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 121 to 129 of 129

Issue DateTitle / Author(s) / CitationFileAltmetrics
2022-09
Association between Body Mass Index and Risk of Gastric Cancer by Anatomic and Histologic Subtypes in Over 500,000 East and Southeast Asian Cohort Participants
DOI
2022-09
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel +/- Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
DOI
2023-04
Tumor-agnostic efficacy and safety of dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: ROAR basket study
DOI
2023-05
Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis
DOI
2023-07
Associations between Physical Activity and Incidence of Cancer among Overweight Adults in Korea: Results from the Health Examinees-G Study

Choi, Jaesung; Park, JooYong; Kim, Ji-Eun; Lee, Miyoung; Kang, Daehee; Shin, Aesun; Choi, Ji-Yeob

Cancer Prevention Research, Vol.16 No.7, pp.405-418

DOI
2023-08
BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non-Small Cell Lung Cancer
DOI
2023-08
Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens
DOI
2023-10
ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2–Positive Gastric or Gastroesophageal Junction Adenocarcinoma
DOI
2024
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study
DOI
1 2 3 4